Deals this week: Sucampo Pharmaceuticals, Satsuma Pharmaceuticals, Nanjing Hicin Pharmaceutical

Sucampo Pharmaceuticals has made plans for a private placement of convertible senior notes, due 2021.

The company expects to raise $225m from the placement and plans to use the proceeds to repay existing debts and for general corporate purposes.

Satsuma Pharmaceuticals has raised $12m in a venture financing round led by RA Capital Management and TPG Biotechnology Partners.

Chinese pharmaceutical company, Nanjing Hicin Pharmaceutical has announced an initial public offering (IPO) of shares to raise ¥22.22bn ($3.19bn) in gross proceeds.

The company will offer two billion shares of its common stock at a price of ¥11.11 ($1.59) a share, as part of the transaction.

US-based pharmaceutical company Braeburn Pharmaceuticals is set to raise gross proceeds of $150m through an initial public offering (IPO) of shares of its common stock.

The company has filed a registration statement with the US Securities and Exchange Commission (SEC) for the same amount.

US-based biopharmaceutical company Kasten and pharmaceutical company Thru Pharma have announced a 50:50 joint venture (JV) to promote the development and marketing of Site Specific Penetration Technology (SSPT) biopharmaceutical products.

Thru Pharma expects the JV to help develop its biopharmaceutical product pipeline.

IntelGenx Technologies subsidary IntelGenx has entered a co-development and commercialisation agreement with Endo Ventures, a subsidiary of Endo International, for a new product utilising IntelGenx' proprietary VersaFilm in the US market.

The agreement gives Endo Ventures rights to commercialise VersaFilm in the US market and share the profits as a result of commercialisation with IntelGenx, which will receive both upfront payment and future milestone payments for VersaFilm from Endo Ventures.

Apple Tree Partners has agreed to invest $40m in the company and will control a majority of the voting power in the company following the IPO.

US-based biotechnology company, Ascletis Pharmaceuticals (Hangzhou) has closed a series B venture financing round to raise ¥700m ($100.77m) in gross proceeds.

The proceeds are intended to be used to expand the company’s product portfolio and sales force.

A three-year co-promotion agreement has been signed between Canadian pharmaceutical company, Concordia International, and Israel-based biopharmaceutical company, RedHill Biopharma.

RedHill Biopharma will increase the promotion of irritable bowel syndrome Donnatal among US doctors promoting the product in up to 30 sales territories in the US over three years, as part of the agreement.

In a series C financing round led by Huaxin Century Investment Group, Chinese biotechnology company Nanjing Frontier Biotechnologies Company has raised $43m.

The funds are intended to be invested to market Albuvirtide, a long-acting HIV-1 fusion inhibitor, and continue research on other products.

US generic injectable products maker Custopharm has acquired full-ownership rights to two paragraph IV abbreviated new drug application (ANDA) injection products, acetaminophen and testosterone undecanoate.

The former product is a pain management drug, while the latter is a testosterone replacement therapy in adult males.

The products have been acquired from Perrigo Company, a pharmaceutical company based in Ireland.

Taiwan, Chinaese pharmaceutical company Lotus Pharmaceutical has announced its intention to sell licence and sale unit, including entire product rights.

The proposed consideration for the deal is $11m.